Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025)

Mineralys Therapeutics (MLYS) posted Capital Expenditures of $15000.0 for Q4 2025, down 59.46% sequentially from $37000.0 in Q3 2024.

Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025) Analysis & Trends

Mineralys Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at $15000.0 in Q4 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $15000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15000.0 (down 84.38% YoY) and the FY2025 annual result came in at $15000.0, down 84.38% from the prior year.
Capital Expenditures slipped to $15000.0 in Q4 2025 per MLYS's latest filing, from $37000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $59000.0 in Q1 2024 and troughed at $15000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Mineralys Therapeutics	2.27 Bn	1.60 Bn	-	-

Download Data